Download PDF
Drug Res (Stuttg) 2015; 65(08): 410-415
DOI: 10.1055/s-0034-1387718
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Relationship between Tetracyclines’ Structure and Minimal Inhibitory Concentration of Streptococcus spp.

M. Marczak
1   Dofarm, Aksamitna, Błonie, Poland
,
T. Grabowski
2   Polpharma Biologics, Gdańsk, Poland
,
M. Feder
3   Department of Research and Development, Adamed Sp. z o.o., Czosnów, Poland
› Author Affiliations
Further Information

Publication History

received 13 March 2014

accepted 23 July 2014

Publication Date:
25 August 2014 (online)

Also available at
    Permissions and Reprints

Abstract

During the past years, a growing number of bacterial strains have become resistant to tetracyclines. The problem of increasing resistance and lack of susceptibility to tetracyclines applies to strains isolated from both: animals and humans. Basic tools to design new drugs and determining the direction of the search for new molecules is the analysis of the relationship between the chemical structure and the pharmacokinetic and pharmacodynamic parameters. Purpose of this study is to determine the relationship between physicochemical parameters of tetracyclines and MIC50 and MIC90 values determined for Streptococcus spp. Analysis of physicochemical parameters of selected drugs was made using MarvinSketch 5.11.5 (ChemAxon Ltd.) and QuickProp 3.1 software from Schrödinger package v 31207. MIC50 and MIC90 values were correlated with 51 calculated physicochemical parameters and arithmetic expressions. Internal and external model validation was performed using leave-one out method. 4 arithmetic expressions fulfilled all validation criteria, but only in relation to MIC50. A new method to optimize the tetracyclines’ structure in relation to Streptococcus spp. was presented. It was also shown that the relations of structure: antimicrobial activity type can have different nature depending on MIC50 or MIC90 of specific bacterial strain.

Key words

in silico - MIC - tetracycline - validation - structure
 

  • References

  • 1 Markiewicz Z, Kwiatkowski ZA. Bakterie, antybiotyki, lekooporność. In: Mostowik K. (ed.) Warszawa: Wydawnictwo Naukowe PWN; 2011. 9,66,133
    Google Scholar
  • 2 The European Union Summary Report on antimicrobial resistance in zoonotic and identicator bacteria from humans, animals and food in 2011. EFSA J 2013; 11: 3196
    PubMedGoogle Scholar
  • 3 EC Commission Decision of 12 June 2007 on a harmonised monitoring of antimicrobial resistance in Salmonella in poultry and pigs. Official Journal of the European Union 2007; L 153/261: 1-4
    PubMedGoogle Scholar
  • 4 Brandon M, Dowzicky MJ. Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial. J Clin Microbiol 2013; 51: 2371-2378
    CrossrefPubMedGoogle Scholar
  • 5 Laurens C, Michon AL, Marchandin H et al. Clinical and antimicrobial susceptibility data of 140 Streptococcus pseudopneumoniae isolates in France. Antimicrob Agents Chemother 2012; 56: 4504-4507
    CrossrefPubMedGoogle Scholar
  • 6 Nomoto R, Tien le HT, Sekizaki T et al. Antimicrobial susceptibility of Streptococcus gallolyticus isolated from humans and animals. Jpn J Infect Dis 2013; 66: 334-336
    CrossrefPubMedGoogle Scholar
  • 7 ECDC Transatlantic Taskforce on Antimicrobial Resistance, Recommendations for future collaboration between the U.S. and EU. 2011; 1-42
    PubMedGoogle Scholar
  • 8 Brodersen DE, Clemons WM, Carter AP et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin b on the 30s ribosomal subunit. Cell 2000; 103: 1143-1154
    CrossrefPubMedGoogle Scholar
  • 9 Jenner L, Starosta AL, Terry DS et al. Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis. Proc Natl Acad Sci 2013; 110: 3812-3816
    CrossrefPubMedGoogle Scholar
  • 10 Chopra I. Tetracycline analogs whose primary target is not the bacterial ribosome. J Antimicrob Agents Chemother 1994; 38: 637-40
    CrossrefPubMedGoogle Scholar
  • 11 Chopra I, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 1992; 29: 245-77
    CrossrefPubMedGoogle Scholar
  • 12 Dax SL. Antibacterial chemotherapeutic agents. 1st ed. London, United Kingdom: Blackie Academic and Professional; 1997: 1-416
    CrossrefGoogle Scholar
  • 13 Mitscher LA. The chemistry of the tetracycline antibiotics. New York, N.Y: Marcel Dekker, Inc; 1978
    Google Scholar
  • 14 Rogalski W. Chemical modification of the tetracyclines. In: Hlavka JJ, Boothe JH. (ed.) Handbook of experimental pharmacology. Vol. 78. Berlin: Springer-Verlag KG; 1985: 179-316
    CrossrefGoogle Scholar
  • 15 Zakeri B, Wright GD. Chemical biology of tetracycline antibiotics. Biochem Cell Biol 2008; 86: 124-136
    CrossrefPubMedGoogle Scholar
  • 16 The Antimicrobial Index, Knowledgebase, version 1.8. TOKU-E, 2013. antibiotics.toku-e.com
    PubMed
  • 17 Ioakimidis L, Thoukydidis L, Mirza A et al. Benchmarking the Reliability of QikProp. Correlation between experimental and predicted values. QSAR Comb. Sci 2007; 27: 445-456
    PubMedGoogle Scholar
  • 18 QuicProp 3.1 from Schrödinger v 31207. Available from Schrödinger, LLC 2007 http://www.schrodinger.com/products/14/17/
    PubMed
  • 19 Grabowski T, Jaroszewski JJ, Gad SC et al. Correlation between in silico physicochemical characteristics of drugs and their mean residence time in human and dog. Int J Toxicol 2012; 31: 25-33
    CrossrefPubMedGoogle Scholar
  • 20 OECD The report from the expert group on (Quantitative) Structure-Activity Relationships [(Q)SARs] on the principles for the validation of (Q)SARs. 2004; 11-198
    PubMedGoogle Scholar
  • 21 OECD Guidance document on the validation of (quantitative) structure-activity relationships [(Q)SAR] models, OECD. 2007; series on testing and assessment No. 69 1-154
    PubMedGoogle Scholar
  • 22 Kubinyi H. QSAR: Hansch analysis and related approaches. Methods and principles. Weinheim: Vol. 1. Wiley-VCH; 1993: 20-190
    Google Scholar
  • 23 Pratim RP, Paul S, Mitra I et al. On two novel parameters for validation of predictive QSAR models. Molecules 2009; 14: 1660-1701
    CrossrefPubMedGoogle Scholar
  • 24 Leardi R. Nature-inspired methods in chemometrics: genetic algorithms and artificial neural networks: genetic algorithms and artificial neural networks. 1st ed Elsevier Science; 2003
    Google Scholar
  • 25 Tonn S, Rowland M. Quantitative structure pharmacokinetic activity relationships with some tetracyclines [proceedings]. J Pharm Pharmacol 1979; 31 (Suppl): 43)
    PubMedGoogle Scholar
  • 26 Topliss J. Quantitative Structure-Activity Relationships of Drugs. London: 1st ed. Academic Press; 1983: 87
    Google Scholar
  • 27 Liu Y, Ramamurthy N, Marecek J et al. The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). Curr Med Chem 2001; 8: 243-252
    CrossrefPubMedGoogle Scholar
  • 28 Di Stefano A, Sozio P, Iannitelli A et al. Characterization of alkanoyl-10-O-minocyclines in micellar dispersions as potential agents for treatment of human neurodegenerative disorders. Eur J Pharm Sci 2008; 34: 118-128
    CrossrefPubMedGoogle Scholar
  • 29 Kuhn P, Eyer K, Allner S et al. A microfluidic vesicle screening platform: monitoring the lipid membrane permeability of tetracyclines. Anal Chem 2011; 23: 8877-85
    PubMedGoogle Scholar
  • 30 Maffeis L, Veraldi S. Minocycline in the treatment of acne: latest findings. G Ital Dermatol Venereol 2010; 145: 425-429
    PubMedGoogle Scholar
  • 31 Fuoco D. Classification framework and chemical biology of tetracycline-structure-based drugs. Antibiotics 2012; 1: 1-13
    CrossrefPubMedGoogle Scholar